Skip to main content

Eurobio Scientific: Eurobio Scientific’s proprietary PCR test confirmed as part of the fight against COVID-19

Written by Customer Service on . Posted in Public Companies.

Eurobio Scientific’s proprietary PCR test confirmed
as part of the fight against COVID-19Paris, May 11, 2020 – 5 :45 pmEurobio Scientific (FR0013240934, ALERS, eligible PEA-PME), a leading French group in the field of specialty in vitro medical diagnostics, announces today that its proprietary test EBX 041 SARS COV-2 for the detection of the genome of the virus responsible for the Covid-19 disease, under license from the Institut Pasteur and CE marked, is part of the list of “Devices CE marked or validated by a CNR, reimbursed by the French national health insurance ”as published by the French administration1 on May 5, 2020.A proprietary test designed, developed and manufactured in FranceEBX 041 SARS COV-2 is a multiplexed real-time PCR test directly usable on a large number of open thermocycling instruments, which can be found in many diagnostic laboratories. It allows the detection, in 1 hour and 15 minutes after extraction, of the identification genes of the SARS COv2 virus as recommended by the World Health Organization (WHO).The EBX 041 SARS CoV2 proprietary multiplex kit, under license from the Institut Pasteur, follows the recommended design by testing 3 targets for virus identification and 1 target for control integrated into each patient test.The test is produced in-house by Eurobio, at its recently renovated Ulis premises, and follows the ISO 13481 regulatory standard process. The current production capacity is 100,000 tests per day.Denis Fortier, Deputy General Manager of Eurobio Scientific says: “Beyond the CE marking which allows us to sell throughout Europe, the official confirmation of our test is one of the important steps to endorse and demonstrate reliability and quality of our reagents. I would like to thank our employees who do their utmost to ensure production volume in line with the current demand for tests.”  Next financial meeting
Eurobio Scientific 2020 annual shareholders meeting: June 23, 2020

1 https://solidarites-sante.gouv.fr/IMG/pdf/liste-reactifs-diagnostic-rt-pcr.pdf
Attachment200511PR-Eurobio Scientific confirmation EBX041_EN

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.